Equal rates of bone healing and reduced surgical time with iliac crest allograft compared to autograft in medial opening wedge high tibial osteotomy: a randomized controlled clinical trial.

INTRODUCTION: Iliac crest autograft is frequently used to fill in bone defects after osteotomies. Nonetheless, surgery for bone autograft procurement is associated with morbidity and pain at the donor site. Alternatives to it have been explored, but there is no consensus to guide their application as a routine practice in several orthopedic procedures. Thus, this study was designed to compare the efficacy and safety between iliac crest autograft and allograft in medial opening wedge high tibial osteotomy. MATERIALS AND METHODS: Forty-seven patients with a symptomatic unilateral genu varum and an indication for high tibial osteotomy were randomly assigned to receive either autograft or allograft to fill the osteotomy site. Operative time, bone healing, and complication rates (delayed union, nonunion, superficial and deep infection, loss of correction, and hardware failure) were recorded after a one-year follow-up. Data were expressed as Mean ± Standard Deviation and considered statistically significant when p < 0.05. RESULTS: The time to radiologic union was similar between both groups (Allograft: 2.38 ± 0.97 months vs. Autograft: 2.45 ± 0.91 months; p = 0.79). Complication rates were also similar in both groups, with one infection in the allograft group and two in the autograft group, two delayed unions in the allograft group, and three in the autograft group. The operative time differed by 11 min between the groups, being lower in the allograft group (Allograft: 65.4 ± 15.1 min vs. Autograft: 76.3 ± 15.2 min; p = 0.02). CONCLUSION: Iliac crest allografts can be safely and effectively used in medial opening wedge high tibial osteotomy as it promotes the same rates of bone union as those achieved by autologous grafts, with the benefits of a shorter operative time. TRIAL REGISTRATION NUMBER: U1111-1280-0637 1 December 2022, retrospectively registered.

MANEJO DO HIPERTENSO COM FIBRILAÇÃO ATRIAL. O QUE MUDOU NA PRÁTICA MÉDICA? / HYPERTENSION AND ATRIAL FIBRILLATION: RECENT ADVANCES

A fibrilação atrial (FA) é a arritmia cardíaca sustentada mais comum na prática clínica. Estima se que 1 a 2% da população mundial seja acometida dessa arritmia e ainda se reconhece que este número está subestimado, dado que até um terço dos pacientes com FA são assintomáticos. Além dos fatores de risco clássicos como diabetes, doença valvar, infarto do miocárdio e insuficiência cardíaca, insuficiência renal crônica, obesidade e apneia obstrutiva do sono, a hipertensão tem um papel muito impactante no surgimento da FA pela sua alta prevalência, com isso sendo o fator de risco mais comum para o desenvolvimento de FA. O manejo adequado da HA é importante para prevenção da FA, controle do ritmo, insuficiência cardíaca e prevenção do acidente vascular cerebral (AVC). O tratamento deve ser integrado por equipe multidisciplinar, individualizando caso a caso, estando sujeito a mudanças ao longo do tempo, com o desenvolvimento de novos fatores de risco, sintomas, progressão da doença e com advento de novos tratamentos. Algumas drogas, tais como os BRAs e iECA parecem apresentar mecanismos específicos de atuação na redução do risco de arritmias. A ablação por cateter pode ser a estratégia mais eficaz para manutenção do ritmo sinusal, em paciente sintomáticos. O objetivo dessa revisão é resumir os dados atuais referente ao manejo do paciente hipertenso com fibrilação atrial.

Worldwide, AF is the most common sustained cardiac arrhythmia in adults. The currently estimated prevalence and incidence in the world are rising, owing to extended longevity and increased survival with chronic diseases. This multifactorial arrhythmia is intertwined with common concomitant cardiovascular diseases, which share classical cardiovascular risk factors, including hypertension, diabetes mellitus, heart failure (HF), coronary artery disease (CAD), chronic kidney disease (CKD), obesity, and obstructive sleep apnoea (OSA). The most common risk factor for AF in the general population is hypertension, and in these patients, left ventricular hypertrophy followed by left atrial enlargement creates the anatomical substrate for AF. Adequate management of hypertension is important for AF prevention, rhythm control, heart failure, and stroke prevention. Integrated management of AF patients requires a coordinated and agreed patient-individualized care pathway to deliver optimized treatment by an interdisciplinary team. The effect of some anti hypertensives, such as RAAS Inhibitors seems to be superior to other antihypertensive treatment to prevent AF recurrences in hypertensive patients with paroxysmal AF beyond the BP reduction. Guidelines suggest a more prominent role for radiofrequency ablation in the treatment of atrial fibrillation (AF), including its use as first-line therapy in recurrent symptomatic paroxysmal or persistent AF in whom a rhythm control strategy is chosen. The objective of this review is to summarize current data on the hypertension in relation to AF, their management, and ongoing research in the field.

Isometric handgrip training does not improve quality of life in hypertensives / Treinamento isométrico com handgrip não melhora qualidade de vida em hipertensos

Hypertensive patients have high blood pressure and poor cardiovascular health and it is known that hypertension negatively affects people's health-related quality of life. Meta-analyses have shown that isometric handgrip training (IHT) reduces blood pressure in hypertensives, but the effects of IHT on health-related quality of life is unknown. Therefore, we tested the hypotheses that the IHT improves health-related quality of life in hypertensives. In this randomized controlled trial, 48 hypertensive individuals were randomly assigned to two groups: IHT and control. IHT was completed thrice weekly (4 × 2 min at 30% of maximal voluntary contraction). Before and after 12 weeks healthrelated quality of life was assessment through Medical Outcomes Study Questionnaire Short Form 36 (SF36). No significant effect was observed for physical function (IHT: 85.6±4.6 vs. 81.1±7.2; Control: 78.6±76.7±4.9), physical problems (IHT: 71.4±10.1vs. 83.9±8.1; Control: 73.8±8.2 vs. 64.3±8.0), general health (IHT: 56.1±3.7 vs. 57.1±1.9; Control: 54.3±1.6 vs. 57.6±2.1), pain (IHT: 23.6±4.6 vs. 30.7±5.8; Control: 32.9±4.5 vs. 31.9±4.3), social aspects (IHT: 46.4±3.6 vs. 50.0±2.3; Control: 48.8±2.7 vs. 48.8±1.7), emotional problems (IHT: 85.7±8.4 vs. 92.9±5.2; Control: 79.4±7.8 vs. 71.4±6.6), mental health (IHT: 61.7±2.8 vs. 58.0±2.5; Control: 54.5±2.4 ± 55.6±1.9), and vitality (IHT: 60.0±4.3 vs. 58.6±4.0; Control: 50.7±2.9 vs. 53.6±3.0) after 12-weeks of supervised IHT (p>0.05 for all). In conclusion, 12-weeks of IHT does not improve health-related quality of life in hypertensives. Therefore, in order to improve quality of life, other exercises should be an indicated for hypertensive patients...(AU)

Pacientes hipertensos têm pressão arterial elevada e saúde cardiovascular prejudicada, e, sabese que a hipertensão também afeta negativamente a qualidade de vida relacionada a saúde. Meta-análises têm demonstrado que o treinamento de exercício isométrico com handgrip (IHT) reduz pressão arterial, mas os efeitos do IHT na qualidade de vida relacionada a saúde são esconhecidos. Portanto, foi testado a hipótese que o IHT melhora a qualidade de vida relacionada a saúde em hipertensos. Nesse ensaio clínico controlado randomizado, 48 hipertensos foram randomizados em IHT e controle. IHT foi realizado três vezes semanais (4 x 2 minutos a 30% da contração voluntária máxima). Antes e após 12 semanas, a qualidade de vida relacionada a saúde foi avaliada pelo Medical Outcomes Study Questionnaire Short Form 36. Nenhum efeito significante foi observado para função física (IHT: 85,6±4,6 vs. 81,1±7,2; Controle: 78,6±76,7±4,9), problemas físicos (IHT: 71,4±10,1 vs. 83,9±8,1; Controle: 73,8±8,2 vs. 64,3±8,0), estado geral de saúde (IHT: 56,1±3,7 vs. 57,1±1,9; Controle: 54,3±1,6 vs. 57,6±2,1), dor (IHT: 23,6±4,6 vs. 30,7±5,8; Controle: 32,9±4,5 vs. 31,9±4,3), aspectos sociais (IHT: 46,4±3,6 vs. 50,0±2,3; Controle: 48,8±2,7 vs. 48,8±1,7), problemas emocionais (IHT: 85,7±8,4 vs. 92,9±5,2; Controle: 79,4±7,8 vs. 71,4±6,6), saúde mental (IHT: 61,7±2,8 vs. 58,0±2,5; Controle: 54,5±2,4 ± 55,6±1,9), e vitalidade (IHT: 60,0±4,3 vs. 58,6±4,0; Controle: 50,7±2,9 vs. 53,6±3,0) após 12 semanas de IHT (p>0.05 para todos). Em conclusão, 12 semanas de IHT não melhora a qualidade de vida relacionada a saúde em hipertensos. Portanto, para melhorar a qualidade de vida, outras modalidades de exercício deveriam ser indicadas para pacientes hipertensos...(AU)

Cardiac Resynchronization Therapy in a Chagasic Patient With Persistent Left Superior Vena Cava.

This report describes the case of a woman with Chagas' cardiomyopathy with severe left ventricular dysfunction and persistent left superior vena cava who presented with episodes of syncope without prodromes and who was referred for cardiac resynchronization therapy. Despite this venous anomaly, electrodes were safely positioned in suitable locations. (Level of Difficulty: Intermediate.).

Saccharomyces cerevisiae asparaginase II, a potential antileukemic drug: Purification and characterization of the enzyme expressed in Pichia pastoris.

Asparaginase obtained from Escherichia coli and Erwinia chrysanthemi are used to treat acute lymphocytic leukaemia and non-Hodgkin's lymphoma. However, these agents cause severe adverse effects. Saccharomyces cerevisiae asparaginase II, encoded by the ASP3 gene, could be a potential candidate for the formulation of new drugs. This work aimed to purify and characterize the periplasmic asparaginase produced by a recombinant Pichia pastoris strain harbouring the ASP3 gene. The enzyme was purified to homogeneity with an activity recovery of 51.3%. The estimated molecular mass of the enzyme was 136 kDa (under native conditions) and 48.6 kDa and 44.6 kDa (under reducing conditions), suggesting an oligomeric structure. The recombinant asparaginase is apparently non-phosphorylated, and the major difference between the monomers seems to be their degree of glycosylation. The enzyme showed an isoelectric point of 4.5 and maximum activity at 46 °C and pH 7.2, retaining 92% of the activity at 37 °C. Circular dichroism and fluorescence analyses showed that the enzyme structure is predominantly α-helical with the contribution of ß-sheet and that it remains stable up to 45 °C and in the pH range of 6-10. In vitro tests indicated that the recombinant asparaginase demonstrated antitumoural activity against K562 leukaemic cells.